151 results
NT 10-Q
OPGN
Opgen Inc
17 May 24
Notice of late quarterly filing
5:02pm
services
Collaboration revenue
Total revenue
Operating expenses
Cost of products sold
Cost of services
Research and development, net
General
8-K
EX-10.1
OPGN
Opgen Inc
16 Apr 24
Departure of Directors or Certain Officers
7:22pm
Entities”), or clients, including without limitation any of their actual or anticipated business, research or development, any of their technology … such Creation (i) relates in any way to the business or to the current or anticipated research or development of the Company or any of its Affiliated
SC 14F1
OPGN
Opgen Inc
3 Apr 24
Statement regarding change in majority of directors
5:29pm
of the Scientific Advisory Committee of the Global Antibiotic Research and Development Partnership (GARDP), a DNDi/WHO initiative, the Chairperson of the Clinical … of Cologne.
Johannes Bacher. Mr. Bacher has over 20 years of research and development and managerial experience along with extensive expertise
8-K
EX-10.1
OPGN
Opgen Inc
29 Mar 24
OpGen Announces Acquisition of Preferred Stock by David Lazar
2:35pm
, records, data, know-how, techniques, designs, machinery, devices, research and development projects, data, preparations, business forms, strategies
8-K
EX-10.4
xhdygwxqs
29 Mar 24
OpGen Announces Acquisition of Preferred Stock by David Lazar
2:35pm
8-K
EX-99.1
mde04
14 Nov 23
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
4:40pm
8-K
EX-99.1
l5psp96 o3axdd5sej
10 Aug 23
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
4:31pm
8-K
EX-99.1
qbb9ja
15 May 23
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
5:11pm
8-K
37o7vngz0gzuodqy
4 May 23
OpGen Announces Pricing of $3.5 Million Public Offering
4:47pm
8-K
EX-99.1
7lt4ptwb
4 May 23
OpGen Announces Pricing of $3.5 Million Public Offering
4:47pm
8-K
EX-99.2
k92z 55uoce
4 May 23
OpGen Announces Pricing of $3.5 Million Public Offering
4:47pm